The FDA granted priority review to the sBLA for isatuximab plus bortezomib/lenalidomide/dexamethasone for newly diagnosed, transplant-ineligible myeloma.
Augusta library to host Passion and Nostalgia concert May 16 centralmaine.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from centralmaine.com Daily Mail and Mail on Sunday newspapers.
Sanofi stops development of tusamitamab ravtansine europeanpharmaceuticalreview.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from europeanpharmaceuticalreview.com Daily Mail and Mail on Sunday newspapers.
Sanofi announces end of program evaluating tusamitamab ravtansine after a 2L NSCLC Phase 3 trial did not meet a primary endpoint CARMEN-LC03 trial did not meet dual primary endpoint of.